Strata Critical Medical says fiscal Q2 ended June 30, 2026 results driven by accelerating Clinical revenue growth and higher margins

• Strata Critical Medical posted Q2 2026 revenue of $72.5 million, up 60.7%, driven by Clinical growth and recent acquisitions.
• Clinical revenue rose 22.6% sequentially to $24.3 million; organic Clinical growth was 15.1%, led by 23.8% growth in Transplant Clinical.
• Clinical gross margin improved to 26.1% from 25.0%; total gross margin rose to 21.0% as mix shifted toward higher-margin Clinical services.
• Logistics revenue rose about 1% sequentially; gross margin fell to 18.4% on fuel surcharge effects, short-trip mix, maintenance costs, and lower ground margins.
• Guidance was raised to $285-295 million revenue, $33-35 million Adjusted EBITDA; a 3% Logistics revenue headwind is expected in Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Strata Critical Medical Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.